含2型口服脊髓灰质炎病毒疫苗的疫情应对策略
尽管2016年前全球停止含2型口服脊髓灰质炎病毒疫苗(OPV2)的计划资金充足,但截至2022年,2型循环疫苗衍生脊髓灰质炎病毒(cVDPV2)的持续传播仍然广泛存在,2016年以来累计病例超过2500例。研究更新全球脊髓灰质炎病毒传播模型,探索不同疫苗及应对范围、延迟、免疫强度、目标年龄组和轮次假设下的应对选项。结果表明,要成功阻断全球cVDPV2传播,需解决紧急疫情应对政策与实施缺陷, urgent行动缩短应对时间、覆盖更大规模人群(尤其高传播地区)并提高接种覆盖率;在nOPV2供应有限时,立即密集使用mOPV2,必要时再密集使用nOPV2,可大幅提高全球阻断cVDPV2传播的概率。
要点
- 2016年以来cVDPV2累计病例超过2500例,持续传播广泛存在。
- 模型显示需解决紧急应对政策与实施缺陷,缩短应对时间并扩大目标人群。
- nOPV2供应有限时,立即密集使用mOPV2,必要时再密集使用nOPV2,可大幅提高阻断概率。
核心结论
- 要成功阻断全球cVDPV2传播,国家和全球消灭脊髓灰质炎倡议需解决紧急疫情应对政策与实施缺陷。
- 脊髓灰质炎规划必须紧急行动,大幅缩短应对时间、覆盖更大规模人群(尤其高传播地区)并提高接种覆盖率。
- 鉴于目前nOPV2供应有限,立即密集使用mOPV2,必要时再密集使用nOPV2,可大幅提高全球阻断cVDPV2传播的概率。
研究设计与样本
- 更新现有全球脊髓灰质炎病毒传播模型,探索不同疫苗及应对范围、延迟、免疫强度、目标年龄组和轮次假设下的应对选项。
主要发现
- 2016年以来cVDPV2累计病例超过2500例。
- 先前分析使用固定应对假设,但疫情应对实施可能变化。
- 模型结果提示,解决紧急应对政策与实施缺陷对成功阻断全球cVDPV2传播至关重要。
临床怎么用
- 脊髓灰质炎规划必须紧急行动,大幅缩短应对时间、覆盖更大规模人群(尤其高传播地区)并提高接种覆盖率。
- nOPV2供应有限时,立即密集使用mOPV2,必要时再密集使用nOPV2,可大幅提高全球阻断cVDPV2传播的概率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite exhaustive and fully-financed plans to manage the risks of globally coordinated cessation of oral poliovirus vaccine (OPV) containing type 2 (OPV2) prior to 2016, as of 2022, extensive, continued transmission of circulating vaccine-derived polioviruses (cVDPVs) type 2 (cVDPV2) remains. Notably, cumulative cases caused by cVDPV2 since 2016 now exceed 2,500. Earlier analyses explored the implications of using different vaccine formulations to respond to cVDPV2 outbreaks and demonstrated how different properties of novel OPV2 (nOPV2) might affect its performance compared to Sabin monovalent OPV2 (mOPV2). These prior analyses used fixed assumptions for how outbreak response would occur, but outbreak response implementation can change. We update an existing global poliovirus transmission model to explore different options for responding with different vaccines and assumptions about scope, delays, immunization intensity, target age groups, and number of rounds. Our findings suggest that in order to successfully stop all cVDPV2 transmission globally, countries and the Global Polio Eradication Initiative need to address the deficiencies in emergency outbreak response policy and implementation. The polio program must urgently act to substantially reduce response time, target larger populations - particularly in high transmission areas - and achieve high coverage with improved access to under-vaccinated subpopulations. Given the limited supplies of nOPV2 at the present, using mOPV2 intensively immediately, followed by nOPV2 intensively if needed and when sufficient quantities become available, substantially increases the probability of ending cVDPV2 transmission globally.
引用
- Kalkowska DA, Wassilak SGF, Pallansch MA, et al. Outbreak response strategies with type 2-containing oral poliovirus vaccines. Vaccine. 2022. PMID: 36402659. doi:10.1016/j.vaccine.2022.10.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。